First Horizon Advisors Inc. boosted its holdings in Grifols, S.A. (NASDAQ:GRFS) by 8,984.6% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,362 shares of the biotechnology company’s stock after acquiring an additional 2,336 shares during the quarter. First Horizon Advisors Inc.’s holdings in Grifols were worth $107,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of GRFS. US Bancorp DE boosted its holdings in shares of Grifols by 17.1% in the 2nd quarter. US Bancorp DE now owns 16,076 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 2,345 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Grifols by 18.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 7,494 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 1,177 shares in the last quarter. Citigroup Inc. boosted its holdings in shares of Grifols by 6.0% in the 2nd quarter. Citigroup Inc. now owns 304,371 shares of the biotechnology company’s stock worth $5,281,000 after purchasing an additional 17,360 shares in the last quarter. Atria Investments LLC boosted its holdings in Grifols by 15.3% during the 2nd quarter. Atria Investments LLC now owns 97,866 shares of the biotechnology company’s stock valued at $1,698,000 after acquiring an additional 12,961 shares during the period. Finally, Susquehanna Fundamental Investments LLC boosted its holdings in Grifols by 170.3% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 72,449 shares of the biotechnology company’s stock valued at $1,257,000 after acquiring an additional 45,645 shares during the period. Hedge funds and other institutional investors own 14.09% of the company’s stock.
GRFS has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft cut Grifols from a “buy” rating to a “hold” rating in a report on Thursday, November 4th. JPMorgan Chase & Co. dropped their price objective on Grifols from €15.00 ($17.05) to €11.00 ($12.50) in a report on Tuesday, January 4th. Citigroup upgraded Grifols from a “neutral” rating to a “buy” rating in a report on Wednesday, October 6th. Zacks Investment Research upgraded Grifols from a “sell” rating to a “hold” rating in a report on Wednesday, November 17th. Finally, Barclays cut Grifols from an “overweight” rating to an “underweight” rating in a report on Tuesday, October 19th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Grifols currently has an average rating of “Hold” and a consensus target price of $15.50.
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy.
Further Reading: Shanghai Stock Exchange Composite Index
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFS).
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.